Brazil · Delayed Price · Currency is BRL Blau Farmacêutica Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 10% in H1 2026 with margin expansion, strong cash generation, and improved working capital. Growth is expected to accelerate in H2, driven by new production lines and product launches, while disciplined capital allocation and operational efficiency remain priorities.
-
Revenue grew 17% year-over-year with margin expansion and zero leverage, driven by strong public and private channel performance and robust product launches. New production lines and pipeline approvals are expected to accelerate growth, with EBITDA margin set to improve further.
Fiscal Year 2025
-
2025 saw record investments, improved margins, and a 39% net income increase despite a 3% revenue drop due to bid delays and product mix changes. Strategic focus on biosimilars, capacity expansion, and new launches positions the company for accelerated growth and reduced volatility in 2026.
-
Revenue and gross margin remained strong, with margin expansion driven by Bergamo's turnaround and favorable sales mix. Capacity constraints limited growth, but major investments in new production lines and R&D are set to drive a 70% production increase and 60% more launches over the next three years.
-
Revenue remained stable year-over-year amid capacity constraints, but gross margin and EBITDA reached post-pandemic highs. New production lines, a strong pipeline, and the Prothya exit position the company for accelerated growth and strategic investments.
-
Revenue grew 4% year-over-year in Q1 2025, with strong 15% growth in the private hospital segment and a 50% increase in net income. Investments in biotechnology and new product launches support a robust outlook, despite temporary impacts from regulatory and supply chain transitions.
Fiscal Year 2024
-
Achieved record quarterly revenue of BRL 474 million, up 31% year-over-year, with strong growth in the hospital segment and improved margins. R&D investment remained high, and integration of Bergamo advanced, while focus shifted to private market sales and Latin American expansion.
-
Q2 2024 saw record revenue and margin expansion, driven by strong private market growth, new product launches, and operational efficiencies. Strategic investments in R&D, capacity, and partnerships position the company for continued growth, with robust cash and low leverage.